Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0805
    +0.0012 (+0.11%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2640
    +0.0018 (+0.14%)
     
  • USD/JPY

    151.2070
    -0.1650 (-0.11%)
     
  • Bitcoin USD

    70,222.53
    -562.19 (-0.79%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Arena Pharmaceuticals receives $500K milestone payment from Eisai

Arena Pharmaceuticals (ARNA) announced that Eisai (ESALY) subsidiary Eisai Limited, based in Mississauga, Ontario, has submitted a New Drug Submission for Belviq (lorcaserin HCl) with Health Canada. Belviq is being evaluated in Canada as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adult obese or overweight patients in the presence of at least one additional cardiovascular risk factor. In connection with the NDS, Arena will receive a milestone payment of $500K from Eisai.

Advertisement